Entresto sacubitril/valsartan regulatory update

FDA approved an NDA from Novartis for Entresto sacubitril/valsartan to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction. On July 7, the pharma said it would begin shipping the drug “very soon” at a wholesale acquisition cost (WAC) of $12.50 a day, less discounts. ...